We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved a new label for Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab) with added safety information. Read More
The European Medicines Agency (EMA) said it is giving a fast-track review to a conditional marketing authorization request from Gilead Sciences for using remdesivir to treat COVID-19 patients. Read More
Recarbio was previously approved for treatment of complicated urinary tract infections and complicated intra-abdominal infections in patients with limited or no alternative treatment options. Read More
NICE did not recommend the treatment due to uncertainty about how stopping the treatment and quality of life affect its cost-effectiveness estimates. Read More
Sarclisa was previously approved in the U.S in combination with pom-dex for the treatment of adults with relapsed refractory multiple myeloma. Read More